Delving into the Latest Updates on Dexamethasone/Piperacillin/Tazobactam with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

GR x β-lactamase

Mechanism

GR agonists(Glucocorticoid receptor agonists), β-lactamase inhibitors(Beta Lactamase inhibitors)

Therapeutic Areas

Otorhinolaryngologic Diseases

Active Indication

Otitis Media

Inactive Indication-

Originator Organization

Yuhan Corp.

Active Organization

Yuhan Corp.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H12N4NaO5S

InChIKeyZUNWFYFXHGWFRA-QVUDESDKSA-N

CAS Registry89785-84-2

View All Structures (3)

ObjectiveTo investigate the efficacy of piperacillin-tazobactam (PIP/TAZ) versus PIP/TAZ plus erythromycin in the treatment of children with bronchopneumonia, and to evaluate the influence of these treatments on inflammatory factors and intestinal flora. Assessing the impact on these parameters is crucial to provide a comprehensive understanding of the treatment effects.MethodsA total of 120 children with bronchial pneumonia who were treated in Yichang Central People's Hospital from April 2018 to April 2020 were randomized (1:1) either into the control group or the observation group. The control group was given PIP/TAZ treatment. The observation group was additionally treated with erythromycin on the basis of the control group. The clinical efficacy, disappearance time of main symptoms and signs, inflammatory factors, and intestinal flora before and after treatment were compared between the two groups.ResultsThe treatment with PIP/TAZ plus erythromycin led to a significantly higher total clinical effective rate versus PIP/TAZ alone (P < .05). PIP/TAZ plus erythromycin resulted in a shorter time taken for the disappearance of fever, cough, and pulmonary rales versus PIP/TAZ alone (P < .05). These findings suggest that the combination regimen was more effective at resolving the key clinical symptoms of bronchopneumonia in children, which is important for improving patient outcomes and reducing the duration of illness. Patients given PIP/TAZ plus erythromycin experienced lower serum levels of the inflammatory markers CRP, TNF-α, and IL-8 as compared with patients given PIP/TAZ alone (P < .05). The reduction in these inflammatory factors indicates that the addition of erythromycin may have provided greater anti-inflammatory benefits beyond the antimicrobial effects of PIP/TAZ alone. Modulating the inflammatory response is clinically significant, as excessive inflammation can contribute to lung damage and disease severity in pneumonia. Conversely, the observation group showed a higher incidence of gastrointestinal disturbances, including increased stool frequency, watery stools, and elevated stool white blood cell counts after treatment (P < .05), suggesting that the erythromycin component may have disrupted the balance of intestinal flora. Maintaining a healthy gut microbiome is important for overall health, immunity, and preventing further complications. The clinical significance of this finding is that the addition of erythromycin to the treatment regimen may have unintended adverse effects on the gut that should be carefully monitored.ConclusionPIP/TAZ plus erythromycin might be a promising candidate in the treatment of children with bronchopneumonia by significantly improving clinical outcomes, shortening the duration of key symptoms, and regulating the level of inflammatory factors. These findings suggest the combination regimen could provide greater clinical benefits compared to PIP/TAZ alone for managing pediatric bronchopneumonia. However, the addition of erythromycin also appeared to aggravate the imbalance of intestinal flora, as evidenced by the increased incidence of gastrointestinal disturbances. Maintaining a healthy gut microbiome is crucial for overall health and immunity in growing children. Therefore, clinicians must carefully weigh the potential benefits of improved antimicrobial and anti-inflammatory effects against the potential risks of disrupting the delicate gut ecosystem when considering the use of antibiotic combinations for pediatric patients. In conclusion, PIP/TAZ plus erythromycin may be a viable treatment option for children with bronchopneumonia, but clinicians should monitor for any unintended impacts on the gut flora and be prepared to make adjustments to the regimen if necessary. Careful consideration of the balance between therapeutic efficacy and preserving intestinal health is essential when prescribing antibiotic combinations, especially in the pediatric population.

01 Dec 2014·BMC Infectious DiseasesQ3 · MEDICINE

Polymerase chain reaction ribotyping of Clostridium difficileisolates in Qatar: a hospital-based study

Q3 · MEDICINE

ArticleOA

Author: Wedad S Hamdi ; Sanjay H Doiphode ; Asma A Al-Thani ; Godwin Justus Wilson ; Naser A Al-Ansari

BACKGROUNDClostridium difficile infection (CDI) is not generally reported to public health authorities in the Middle East and its true prevalence remains largely unknown. The aims of this study were to determine the prevalence of CDI and its associated ribotypes among C. difficile isolates in Qatar. Influence of age and correlation with other risk factors e.g. proton pump inhibitor use, antibiotic use, existence of chronic conditions, etc was also investigated for CDI positive patients.METHODSA total of 1,532 patients with suspected CDI were recruited from two hospitals between 2011 and 2012. C. difficile was identified using glutamate dehydrogenase (GDH) lateral flow assay and toxins A and B Enzyme Immunoassay (EIA). The C. difficile positive samples were then cultured for PCR-ribotyping.RESULTS122 of the 1,532 (7.9%) samples from individual patients were identified as C.difficile positive; and 79 of these were viably cultured (~65%). From these, 36 different PCR ribotypes were isolated, of which strains 258 (6 [7.6%]), 01/014/046 (5 [6.3%]), and 011/053/056/107 (4 [5%]) were the most prevalent. The prevalence of PCR-ribotype 027 was 1.3% (n = 1). An age of ≥65 years and treatment with proton pump inhibitors correlated with higher frequency of CDI. Treatment with third generation cephalosporins (50 [41%]) and piperacillin/tazobactam antibiotics (55 [45.1%]) was most frequently associated with CDI.CONCLUSIONThe most common C. difficile ribotype identified in Qatar was 258, which is different from those found in North America, Europe and Asia. The prevalence of CDI was higher in Qatar than Europe; though comparable to other Middle Eastern countries. These findings underscore the importance of local surveillance to detect and control C. difficile infection.

Revista Española de QuimioterapiaQ4 · MEDICINE

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam

Q4 · MEDICINE

Review

Author: Girón, R M ; Ibáñez, A ; Alarcón, T ; Gómez-Punter, R M

Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs. piperacillin-tazobactam (PIP/TAZ) for treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), demonstrated non-inferiority at all-cause mortality at 28 days (15.9% vs 21.3%), favorable clinical response at 7-14 days end of treatment (61% vs 59.8%) and with minor serious adverse effects (26.7% vs 32%). IMI/REL is a therapeutic option in HAP and VAP at approved dosage imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg once every 6h, by an IV infusion over 30 min.

100 Deals associated with Dexamethasone/Piperacillin/Tazobactam

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Otitis Media	Phase 2	-	Yuhan Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2019	Not Applicable	Pneumonia	43	Cefepime with Ciprofloxacin	kuxcpbahww(xkkhovxffa) = qowzdvbtpv inafrbvyhc (rkxfugwpgh ) View more	-	28 Sep 2019
				Piperacillin/tazobactam with Ciprofloxacin	kuxcpbahww(xkkhovxffa) = ehqibmyyvt inafrbvyhc (rkxfugwpgh ) View more
ASN2018	Not Applicable	-	6	Meropenem	jzcwwahdxd(ohfatpbnay) = zxtcaoxjyb qtnmzuzrpy (gdxuspqmop ) View more	-	23 Oct 2018
				Piperacillin/Tazobactam	jzcwwahdxd(ohfatpbnay) = imlzagaszh qtnmzuzrpy (gdxuspqmop ) View more
Pubmed \| Pharmacotherapy	Not Applicable	Critical Illness	367	Extended-infusion (EI) piperacillin/tazobactam	(sgmttffejr) = tgcnqcidal advnmqdreb (htgasemycy ) View more	-	01 Jan 2017
				Non-extended infusion (NEI) piperacillin/tazobactam	(sgmttffejr) = cjurytfhal advnmqdreb (htgasemycy ) View more
ASN2016	Not Applicable	Acute Kidney Injury	5,370	Vancomycin/Cefepime	qfkwpruein(dpgfcugbkx) = vipfgdhmmr qbzebecduq (igqysdqyho )	Negative	15 Nov 2016
				Vancomycin/Piperacillin-Tazobactam	qfkwpruein(dpgfcugbkx) = acwxpmjikl qbzebecduq (igqysdqyho )